Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Chari et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 502 patients in multiple countries Lower mortality with HCQ (not stat. sig., p=0.17) Chari et al., Blood, doi:10.1182/blood.2020008150 Favors HCQ Favors control

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Chari et al., Blood, doi:10.1182/blood.2020008150
Chari et al., Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International.., Blood, doi:10.1182/blood.2020008150
Dec 2020   Source   PDF  
  All Studies   Meta
Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjusted RR 0.67, p = 0.17 (data is in the supplementary material).
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 24% lower mortality [19‑28%] from meta analysis of the 237 mortality results to date. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 33.1% lower, RR 0.67, p = 0.17, treatment 8 of 29 (27.6%), control 195 of 473 (41.2%), NNT 7.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chari et al., 24 Dec 2020, retrospective, multiple countries, peer-reviewed, median age 69.0, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, Gordon Cook, Noa Biran, Kwee Yong, Vania Hungria, Monika Engelhardt, Francesca Gay, Ana García Feria, Stefania Oliva, Rimke Oostvogels, Alessandro Gozzetti, Cara Rosenbaum, Shaji Kumar, Edward A Stadtmauer, Hermann Einsele, Meral Beksac, Katja Weisel, Kenneth C Anderson, María-Victoria Mateos
High but variable mortality for hospitalized MM patients (27% to 57%). l Uncontrolled MM in the setting of COVID-19 infection was associated with an increased risk of death. The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient-and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
Footnotes For original data, please contact the International Myeloma Society at The online version of this article contains a data supplement. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
Avet-Loiseau, Introduction to a review series on advances in multiple myeloma
Blimark, Holmberg, Mellqvist, Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients, Haematologica
Celgene, Explanation of novelty: This study investigated the characteristics and outcomes of MM patients with COVID-19 infection in 10 countries
Chen, Yu, He, Risk factors for death in 1859 subjects with COVID-19, Leukemia
Clark, Jit, Gash, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study, Lancet Glob Health
Corre, Montes, Martin, Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk, Haematologica
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19: preliminary report
Hultcrantz, Richter, Rosenbaum, COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers [published correction appears, Blood Cancer Discov
Kuderer, Choueiri, Shah, Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet
Lee, Cazier, Angelis, navirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study, Lancet
Mahindra, Laubach, Raje, Munshi, Richardson et al., Latest advances and current challenges in the treatment of multiple myeloma, Nat Rev Clin Oncol
Martínez, Ópez, Mateos, Encinas, Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality, Blood Cancer J
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Pratt, Goodyear, Moss, Immunodeficiency and immunotherapy in multiple myeloma, Br J Haematol
Robilotti, Babady, Mead, Determinants of COVID-19 disease severity in patients with cancer, Nat Med
Robinson, Gyawali, Booth, Risk of COVID-19 in patients with cancer, JAMA Oncol
Salje, Kiem, Lefrancq, Estimating the burden of SARS-CoV-2 in France, Science
Selvan, Risk factors for death from COVID-19 [published correction appears, Nat Rev Immunol
Szalat, Munshi, Novel agents in multiple myeloma, Cancer J
Terpos, Engelhardt, Cook, Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN), Leukemia
Tian, Yuan, Xiao, Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol
Wang, Van Oekelen, Mouhieddine, A tertiary center experience of multiple myeloma IMS COVID-19 INITIAL RESULTS blood® 24 DECEMBER 2020 | VOLUME 136, NUMBER 26 3039 patients with COVID-19: lessons learned and the path forward, J Hematol Oncol
Waszczuk-Gajda, Drozd-Sokołowska, Basak, Infectious complications in patients with multiple myeloma after highdose chemotherapy followed by autologous stem cell transplant: nationwide study of the Infectious Complications Study Group of the Polish Adult Leukemia Group, Transplant Proc
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop